EP2626372 - Bispecific antibodies and methods for production thereof [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 25.01.2019 Database last updated on 09.09.2024 | |
Former | The patent has been granted Status updated on 16.02.2018 | ||
Former | Grant of patent is intended Status updated on 03.10.2017 | Most recent event Tooltip | 10.07.2020 | Lapse of the patent in a contracting state New state(s): IS | published on 12.08.2020 [2020/33] | Applicant(s) | For all designated states Genmab A/S Kalvebod Brygge 43 1560 Copenhagen V / DK | [2018/03] |
Former [2013/33] | For all designated states Genmab A/S Bredgade 34 1260 Copenhagen K / DK | Inventor(s) | 01 /
Schuurman, Janine Genmab B.V. c/o Genmab B.V. Yalelaan 60 3584-CM Utrecht / NL | 02 /
Vink, Tom Schaepmanstraat 25 2406 DB, Alphen aan den Rijn / NL | 03 /
Winkel, Jan Van De Genmab B.V. c/o Genmab B.V. Yalelaan 60 3584-CM Utrecht / NL | 04 /
Labrijn, Aran Frank Genmab B.V. c/o Genmab B.V. Yalelaan 60 3584-CM Utrecht / NL | 05 /
Aalberse, Rob Roosmarijnhof 1 1115-DV Duivendrecht / NL | 06 /
Kolfschoten, Marijn van der Neut Derde Oosterparkstraat 29-hs 1091-JT Amsterdam / NL | 07 /
Parren, Paul Werdorperwaard 17 3984 PR Odijk / NL | [2018/12] |
Former [2013/33] | 01 /
Schuurman, Janine Genmab B.V. c/o Genmab B.V. Yalelaan 60 3584-CM Utrecht / NL | ||
02 /
Vink, Tom Genmab B.V. c/o Genmab B.V. Yalelaan 60 3584-CM Utrecht / NL | |||
03 /
Winkel, Jan Van De Genmab B.V. c/o Genmab B.V. Yalelaan 60 3584-CM Utrecht / NL | |||
04 /
Labrijn, Aran Frank Genmab B.V. c/o Genmab B.V. Yalelaan 60 3584-CM Utrecht / NL | |||
05 /
Aalberse, Rob Roosmarijnhof 1 1115-DV Duivendrecht / NL | |||
06 /
Kolfschoten, Marijn van der Neut Derde Oosterparkstraat 29-hs 1091-JT Amsterdam / NL | |||
07 /
Parren, Paul Genmab B.V. c/o Genmab B.V. Yalelaan 60 3584-CM Utrecht / NL | Representative(s) | Genmab A/S Carl Jacobsens Vej 30 2500 Valby / DK | [N/P] |
Former [2018/12] | Genmab A/S Kalvebod Brygge 43 1560 Copenhagen V / DK | ||
Former [2013/33] | Genmab A/S Bredgade 34 E 1260 Copenhagen K / DK | Application number, filing date | 12199117.8 | 28.03.2008 | [2013/33] | Priority number, date | US20070920840P | 29.03.2007 Original published format: US 920840 P | DK20070000491 | 29.03.2007 Original published format: DK 200700491 | [2013/33] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP2626372 | Date: | 14.08.2013 | Language: | EN | [2013/33] | Type: | B1 Patent specification | No.: | EP2626372 | Date: | 21.03.2018 | Language: | EN | [2018/12] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 16.07.2013 | Classification | IPC: | C07K16/46, C07K16/28, C07K16/00 | [2017/40] | CPC: |
C07K16/468 (EP,US);
A61P31/00 (EP);
A61P35/00 (EP);
C07K16/00 (EP,US);
C07K16/2863 (EP,US);
C07K16/2887 (EP,US);
C07K2317/24 (EP,US);
C07K2317/31 (EP,US);
C07K2317/526 (EP,US);
|
Former IPC [2013/33] | C07K16/46, C07K16/28 | Designated contracting states | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR [2018/12] |
Former [2013/33] | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR | Extension states | AL | 14.02.2014 | BA | 14.02.2014 | MK | 14.02.2014 | RS | 14.02.2014 | Title | German: | Bispezifische Antikörper und Verfahren zu deren Herstellung | [2013/33] | English: | Bispecific antibodies and methods for production thereof | [2013/33] | French: | Anticorps bispécifiques et procédés de production de ceux-ci | [2013/33] | Examination procedure | 14.02.2014 | Examination requested [2014/13] | 21.03.2014 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time | 27.05.2014 | Amendment by applicant (claims and/or description) | 07.08.2015 | Despatch of a communication from the examining division (Time limit: M06) | 17.02.2016 | Reply to a communication from the examining division | 23.08.2017 | Cancellation of oral proceeding that was planned for 13.09.2017 | 13.09.2017 | Date of oral proceedings (cancelled) | 04.10.2017 | Communication of intention to grant the patent | 09.02.2018 | Fee for grant paid | 09.02.2018 | Fee for publishing/printing paid | 09.02.2018 | Receipt of the translation of the claim(s) | Parent application(s) Tooltip | EP08715601.4 / EP2139924 | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20080715601) is 29.12.2010 | Opposition(s) | 02.01.2019 | No opposition filed within time limit [2019/09] | Request for further processing for: | The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report | 27.05.2014 | Request for further processing filed | 27.05.2014 | Full payment received (date of receipt of payment) Request granted | 13.06.2014 | Decision despatched | Fees paid | Renewal fee | 22.04.2013 | Renewal fee patent year 03 | 22.04.2013 | Renewal fee patent year 04 | 22.04.2013 | Renewal fee patent year 05 | 11.03.2013 | Renewal fee patent year 06 | 12.03.2014 | Renewal fee patent year 07 | 10.03.2015 | Renewal fee patent year 08 | 10.03.2016 | Renewal fee patent year 09 | 10.03.2017 | Renewal fee patent year 10 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | HU | 28.03.2008 | CY | 21.03.2018 | CZ | 21.03.2018 | DK | 21.03.2018 | EE | 21.03.2018 | FI | 21.03.2018 | HR | 21.03.2018 | IT | 21.03.2018 | LT | 21.03.2018 | LV | 21.03.2018 | MC | 21.03.2018 | NL | 21.03.2018 | PL | 21.03.2018 | RO | 21.03.2018 | SE | 21.03.2018 | SI | 21.03.2018 | SK | 21.03.2018 | TR | 21.03.2018 | LU | 28.03.2018 | MT | 28.03.2018 | BE | 31.03.2018 | BG | 21.06.2018 | NO | 21.06.2018 | GR | 22.06.2018 | IS | 21.07.2018 | PT | 23.07.2018 | [2020/33] |
Former [2020/28] | HU | 28.03.2008 | |
CY | 21.03.2018 | ||
CZ | 21.03.2018 | ||
DK | 21.03.2018 | ||
EE | 21.03.2018 | ||
FI | 21.03.2018 | ||
HR | 21.03.2018 | ||
IT | 21.03.2018 | ||
LT | 21.03.2018 | ||
LV | 21.03.2018 | ||
MC | 21.03.2018 | ||
NL | 21.03.2018 | ||
PL | 21.03.2018 | ||
RO | 21.03.2018 | ||
SE | 21.03.2018 | ||
SI | 21.03.2018 | ||
SK | 21.03.2018 | ||
TR | 21.03.2018 | ||
LU | 28.03.2018 | ||
MT | 28.03.2018 | ||
BE | 31.03.2018 | ||
BG | 21.06.2018 | ||
NO | 21.06.2018 | ||
GR | 22.06.2018 | ||
PT | 23.07.2018 | ||
Former [2020/16] | CY | 21.03.2018 | |
CZ | 21.03.2018 | ||
DK | 21.03.2018 | ||
EE | 21.03.2018 | ||
FI | 21.03.2018 | ||
HR | 21.03.2018 | ||
IT | 21.03.2018 | ||
LT | 21.03.2018 | ||
LV | 21.03.2018 | ||
MC | 21.03.2018 | ||
NL | 21.03.2018 | ||
PL | 21.03.2018 | ||
RO | 21.03.2018 | ||
SE | 21.03.2018 | ||
SI | 21.03.2018 | ||
SK | 21.03.2018 | ||
TR | 21.03.2018 | ||
LU | 28.03.2018 | ||
MT | 28.03.2018 | ||
BE | 31.03.2018 | ||
BG | 21.06.2018 | ||
NO | 21.06.2018 | ||
GR | 22.06.2018 | ||
PT | 23.07.2018 | ||
Former [2020/08] | CY | 21.03.2018 | |
CZ | 21.03.2018 | ||
DK | 21.03.2018 | ||
EE | 21.03.2018 | ||
FI | 21.03.2018 | ||
HR | 21.03.2018 | ||
IT | 21.03.2018 | ||
LT | 21.03.2018 | ||
LV | 21.03.2018 | ||
MC | 21.03.2018 | ||
NL | 21.03.2018 | ||
PL | 21.03.2018 | ||
RO | 21.03.2018 | ||
SE | 21.03.2018 | ||
SI | 21.03.2018 | ||
SK | 21.03.2018 | ||
LU | 28.03.2018 | ||
MT | 28.03.2018 | ||
BE | 31.03.2018 | ||
BG | 21.06.2018 | ||
NO | 21.06.2018 | ||
GR | 22.06.2018 | ||
PT | 23.07.2018 | ||
Former [2019/26] | CY | 21.03.2018 | |
CZ | 21.03.2018 | ||
DK | 21.03.2018 | ||
EE | 21.03.2018 | ||
FI | 21.03.2018 | ||
HR | 21.03.2018 | ||
IT | 21.03.2018 | ||
LT | 21.03.2018 | ||
LV | 21.03.2018 | ||
MC | 21.03.2018 | ||
NL | 21.03.2018 | ||
PL | 21.03.2018 | ||
RO | 21.03.2018 | ||
SE | 21.03.2018 | ||
SI | 21.03.2018 | ||
SK | 21.03.2018 | ||
LU | 28.03.2018 | ||
BE | 31.03.2018 | ||
BG | 21.06.2018 | ||
NO | 21.06.2018 | ||
GR | 22.06.2018 | ||
PT | 23.07.2018 | ||
Former [2019/12] | CY | 21.03.2018 | |
CZ | 21.03.2018 | ||
DK | 21.03.2018 | ||
EE | 21.03.2018 | ||
FI | 21.03.2018 | ||
HR | 21.03.2018 | ||
IT | 21.03.2018 | ||
LT | 21.03.2018 | ||
LV | 21.03.2018 | ||
MC | 21.03.2018 | ||
NL | 21.03.2018 | ||
PL | 21.03.2018 | ||
RO | 21.03.2018 | ||
SE | 21.03.2018 | ||
SK | 21.03.2018 | ||
LU | 28.03.2018 | ||
BE | 31.03.2018 | ||
BG | 21.06.2018 | ||
NO | 21.06.2018 | ||
GR | 22.06.2018 | ||
PT | 23.07.2018 | ||
Former [2019/08] | CY | 21.03.2018 | |
CZ | 21.03.2018 | ||
DK | 21.03.2018 | ||
EE | 21.03.2018 | ||
FI | 21.03.2018 | ||
HR | 21.03.2018 | ||
IT | 21.03.2018 | ||
LT | 21.03.2018 | ||
LV | 21.03.2018 | ||
MC | 21.03.2018 | ||
NL | 21.03.2018 | ||
PL | 21.03.2018 | ||
RO | 21.03.2018 | ||
SE | 21.03.2018 | ||
SK | 21.03.2018 | ||
LU | 28.03.2018 | ||
BG | 21.06.2018 | ||
NO | 21.06.2018 | ||
GR | 22.06.2018 | ||
PT | 23.07.2018 | ||
Former [2019/06] | CY | 21.03.2018 | |
CZ | 21.03.2018 | ||
EE | 21.03.2018 | ||
FI | 21.03.2018 | ||
HR | 21.03.2018 | ||
IT | 21.03.2018 | ||
LT | 21.03.2018 | ||
LV | 21.03.2018 | ||
MC | 21.03.2018 | ||
NL | 21.03.2018 | ||
PL | 21.03.2018 | ||
RO | 21.03.2018 | ||
SE | 21.03.2018 | ||
SK | 21.03.2018 | ||
LU | 28.03.2018 | ||
BG | 21.06.2018 | ||
NO | 21.06.2018 | ||
GR | 22.06.2018 | ||
PT | 23.07.2018 | ||
Former [2019/04] | CY | 21.03.2018 | |
CZ | 21.03.2018 | ||
EE | 21.03.2018 | ||
FI | 21.03.2018 | ||
HR | 21.03.2018 | ||
IT | 21.03.2018 | ||
LT | 21.03.2018 | ||
LV | 21.03.2018 | ||
NL | 21.03.2018 | ||
PL | 21.03.2018 | ||
RO | 21.03.2018 | ||
SE | 21.03.2018 | ||
SK | 21.03.2018 | ||
LU | 28.03.2018 | ||
BG | 21.06.2018 | ||
NO | 21.06.2018 | ||
GR | 22.06.2018 | ||
PT | 23.07.2018 | ||
Former [2019/03] | CY | 21.03.2018 | |
CZ | 21.03.2018 | ||
EE | 21.03.2018 | ||
FI | 21.03.2018 | ||
HR | 21.03.2018 | ||
IT | 21.03.2018 | ||
LT | 21.03.2018 | ||
LV | 21.03.2018 | ||
NL | 21.03.2018 | ||
PL | 21.03.2018 | ||
RO | 21.03.2018 | ||
SE | 21.03.2018 | ||
SK | 21.03.2018 | ||
BG | 21.06.2018 | ||
NO | 21.06.2018 | ||
GR | 22.06.2018 | ||
PT | 23.07.2018 | ||
Former [2018/50] | CY | 21.03.2018 | |
CZ | 21.03.2018 | ||
EE | 21.03.2018 | ||
FI | 21.03.2018 | ||
HR | 21.03.2018 | ||
IT | 21.03.2018 | ||
LT | 21.03.2018 | ||
LV | 21.03.2018 | ||
NL | 21.03.2018 | ||
PL | 21.03.2018 | ||
RO | 21.03.2018 | ||
SE | 21.03.2018 | ||
SK | 21.03.2018 | ||
BG | 21.06.2018 | ||
NO | 21.06.2018 | ||
GR | 22.06.2018 | ||
Former [2018/49] | CY | 21.03.2018 | |
EE | 21.03.2018 | ||
FI | 21.03.2018 | ||
HR | 21.03.2018 | ||
IT | 21.03.2018 | ||
LT | 21.03.2018 | ||
LV | 21.03.2018 | ||
NL | 21.03.2018 | ||
PL | 21.03.2018 | ||
RO | 21.03.2018 | ||
SE | 21.03.2018 | ||
BG | 21.06.2018 | ||
NO | 21.06.2018 | ||
GR | 22.06.2018 | ||
Former [2018/45] | CY | 21.03.2018 | |
FI | 21.03.2018 | ||
HR | 21.03.2018 | ||
LT | 21.03.2018 | ||
LV | 21.03.2018 | ||
NL | 21.03.2018 | ||
SE | 21.03.2018 | ||
BG | 21.06.2018 | ||
NO | 21.06.2018 | ||
GR | 22.06.2018 | ||
Former [2018/40] | CY | 21.03.2018 | |
FI | 21.03.2018 | ||
HR | 21.03.2018 | ||
LT | 21.03.2018 | ||
LV | 21.03.2018 | ||
SE | 21.03.2018 | ||
BG | 21.06.2018 | ||
NO | 21.06.2018 | ||
GR | 22.06.2018 | ||
Former [2018/37] | CY | 21.03.2018 | |
FI | 21.03.2018 | ||
HR | 21.03.2018 | ||
LT | 21.03.2018 | ||
NO | 21.06.2018 | ||
GR | 22.06.2018 | ||
Former [2018/35] | CY | 21.03.2018 | |
FI | 21.03.2018 | ||
HR | 21.03.2018 | ||
LT | 21.03.2018 | ||
NO | 21.06.2018 | Documents cited: | Search | [X]DE19859115 (LINDHOFER HORST [DE]) [X] 1-7,13-19,25,26,33,35-37 * page 5, lines 44,45,58 * * page 6, lines 53-60 *; | [AD]WO02100348 (GENMAB AS [DK], et al) [AD] 1-37 * the whole document *; | [AD]WO2004035607 (GENMAB AS [DK], et al) [AD] 1-37 * the whole document *; | [XA]WO2005000899 (BIOGEN IDEC INC [US], et al) [X] 35,36 * abstract * * page 1, lines 21-29 * * page 3, lines 21-28 * * page 7, lines 8-14 * * page 4, lines 3-10 * * page 5, lines 15-17 * * page 7, lines 15-17 * * page 8, lines 26-31 * * page 8, line 32 - page 9, line 4 * * page 9, lines 20-27 * * page 11, lines 10-12 * * page 11, lines 19-26 * [A] 1-34,37; | [X]WO2005062916 (CENTOCOR INC [US], et al) [X] 1-7,13-19,25,26,35-37 * page 1, line 27 - page 2, line 1 * * page 3, lines 14-22 * * page 13, lines 31-38 * * page 37, lines 17-20 * * page 67, lines 20-25 * * page 54, line 30 - page 56, line 13 * * page 57, lines 24,25 * * sequences 8,9,14,15 * * page 94, lines 16-20 *; | [XA]WO2006047340 (AMGEN INC [US], et al) [X] 35,36 * page 37, lines 23-27 * * page 26, line 24 - page 27, line 5 * * page 27, lines 6-8 * * page 79, line 21 - page 82, line 18; example 9 * [A] 1-34,37; | [X]EP1693386 (CHUGAI PHARMACEUTICAL CO LTD [JP]) [X] 1-3,13-15,26,35-37 * paragraph [0065] * * paragraphs [0068] - [0073] *; | [AP]WO2007059782 (GENMAB AS [DK], et al) [AP] 1-37 * the whole document *; | [AP]WO2007103112 (ELAN PHARM INC [US], et al) [AP] 1-37* the whole document *; | [XA] - SCHUURMAN J ET AL, "Normal human immunoglobulin G4 is bispecific: It has two different antigen-combining sites", IMMUNOLOGY, BLACKWELL PUBLISHING, OXFORD, GB, (19990801), vol. 97, no. 4, ISSN 0019-2805, pages 693 - 698, XP009104479 [X] 35,36 * abstract * [A] 1-34,37 DOI: http://dx.doi.org/10.1046/j.1365-2567.1999.00845.x | [XA] - SCHUURMAN J ET AL, "The inter-heavy chain disulfide bonds of IgG4 are in equilibrium with intra-chain disulfide bonds", MOLECULAR IMMUNOLOGY, ELMSFORD, NY, US, (20010101), vol. 38, no. 1, ISSN 0161-5890, pages 1 - 8, XP002329378 [X] 35,36 * abstract * * page 7, column L, paragraph 3 * * page 7, column L, paragraph 5 - column R, paragraph 1 * [A] 1-34,37 DOI: http://dx.doi.org/10.1016/S0161-5890(01)00050-5 | [XA] - AALBERSE R C ET AL, "IgG4 breaking the rules", IMMUNOLOGY, BLACKWELL PUBLISHING, OXFORD, GB, (20020101), vol. 105, no. 1, ISSN 0019-2805, pages 9 - 19, XP002987706 [X] 35,36 * page 11, column R, paragraph 2 - page 12, column R, paragraph 1 * [A] 1-34,37 DOI: http://dx.doi.org/10.1046/j.0019-2805.2001.01341.x | [XP] - KOLFSCHOTEN MARIJN VAN DER NEUT ET AL, "Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange", SCIENCE, WASHINGTON, DC, (20070901), vol. 317, no. 5844, ISSN 0036-8075, pages 1554 - 1557, XP009104480 [XP] 1-37 * the whole document * DOI: http://dx.doi.org/10.1126/science.1144603 | [A] - MERCHANT A MARGARET ET AL, "An efficient route to human bispecific IgG", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, (19980701), vol. 16, no. 7, ISSN 1087-0156, pages 677 - 681, XP002141015 [A] 1-37 * the whole document * DOI: http://dx.doi.org/10.1038/nbt0798-677 | [A] - AALBERSE R C ET AL, "THE APPARENT MONOVALENCY OF HUMAN IGG4 IS DUE TO BISPECIFICITY", INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, XX, XX, (19990201), vol. 118, no. 2-4, ISSN 1018-2438, pages 187 - 189, XP009080024 [A] 1-37 * the whole document * DOI: http://dx.doi.org/10.1159/000024062 | [A] - BLOOM J W ET AL, "Intrachain disulfide bond in the core hinge region of human IgG4", PROTEIN SCIENCE, CAMBRIDGE UNIVERSITY PRESS, CAMBRIDGE, GB, (19970101), vol. 6, no. 2, ISSN 0961-8368, pages 407 - 415, XP002329379 [A] 1-37 * the whole document * | [A] - ANGAL S ET AL, "A SINGLE AMINO ACID SUBSTITUTION ABOLISHES THE HETEROGENEITY OF CHIMERIC MOUSE/HUMAN (IGG4) ANTIBODY", MOLECULAR IMMUNOLOGY, ELMSFORD, NY, US, (19930101), vol. 30, no. 1, ISSN 0161-5890, pages 105 - 108, XP000770218 [A] 1-37 * the whole document * DOI: http://dx.doi.org/10.1016/0161-5890(93)90432-B | by applicant | WO9203918 | WO9222645 | WO9301227 | WO9425585 | US5545806 | US5545807 | US5569825 | US5625126 | US5633425 | US5661016 | US5733743 | US5741957 | US5750172 | US5756687 | WO9824884 | US5770429 | US5789650 | US5814318 | US5827690 | US5874299 | US5877397 | WO0109187 | WO0114424 | WO0243478 | WO02100348 | WO2004035607 | WO2005062916 | - AALBERSE, R. C.; R. VAN DER GAAG; J. VAN LEEUWEN, "Serologic aspects of IgG4 antibodies. I. Prolonged immunization results in an IgG4- restricted response", IMMUNOL, (1983), vol. 130, page 722, XP002950400 | - VAN DER ZEE; J. S., P. VAN SWIETEN; R. C. AALBERSE, "Serologic aspects of IgG4 antibodies. II. IgG4 antibodies form small, nonprecipitating immune complexes due to functional monovalency", J IMMUNOL, (1986), vol. 137, page 3566 | - SCHUURMAN, J.; R. VAN REE; G. J. PERDOK; H. R. VAN DOORN; K. Y. TAN; R. C. AALBERSE, "Normal human immunoglobulin G4 is bispecific: it has two different antigen-combining sites", IMMUNOLOGY, (1999), vol. 97, doi:doi:10.1046/j.1365-2567.1999.00845.x, page 693, XP009104479 DOI: http://dx.doi.org/10.1046/j.1365-2567.1999.00845.x | - AALBERSE, R. C.; J. SCHUURMAN, "IgG4 breaking the rules", IMMUNOLOGY, (2002), vol. 105, doi:doi:10.1046/j.0019-2805.2001.01341.x, page 9, XP055115132 DOI: http://dx.doi.org/10.1046/j.0019-2805.2001.01341.x | - AALBERSE, R. C.; J. SCHUURMAN; R. VAN REE, "The apparent monovalency of human IgG4 is due to bispecificity", INT ARCH ALLERGY IMMUNOL, (1999), vol. 118, doi:doi:10.1159/000024062, page 187, XP009080024 DOI: http://dx.doi.org/10.1159/000024062 | - SCHUURMAN, J.; G. J. PERDOK; A. D. GORTER; R. C. AALBERSE, "The inter-heavy chain disulfide bonds of IgG4 are in equilibrium with intra-chain disulfide bonds", MOL IMMUNOL, (2001), vol. 38, doi:doi:10.1016/S0161-5890(01)00050-5, page 1, XP002329378 DOI: http://dx.doi.org/10.1016/S0161-5890(01)00050-5 | - BLOOM, J. W.; M. S. MADANAT; D. MARRIOTT; T. WONG; S. Y. CHAN, "Intrachain disulfide bond in the core hinge region of human IgG4", PROTEIN SCI, (1997), vol. 6, page 407, XP002329379 | - GREGORY, L.; K. G. DAVIS; B. SHETH; J. BOYD; R. JEFFERIS; C. NAVE; D. R. BURTON, "The solution conformations of the subclasses of human IgG deduced from sedimentation and small angle X-ray scattering studies", MOL IMMUNOL, (1987), vol. 24, doi:doi:10.1016/0161-5890(87)90184-2, page 821, XP023683044 DOI: http://dx.doi.org/10.1016/0161-5890(87)90184-2 | - DENG, L.; D. WYLIE; Y. S. TSAO; B. LARKIN; M. VOLOCH; W. L. LING, "Detection and quantification of the human IgG4 half-molecule, HL, from unpurified cell-culture supernatants", BIOTECHNOL APPL BIOCHEM, (2004), vol. 40, doi:doi:10.1042/BA20030174, page 261, XP009080029 DOI: http://dx.doi.org/10.1042/BA20030174 | - MARCIN; ZHU, ACTA PHARMACOL SIN., (2005), vol. 26, page 649 | - CHOTHIA; LESK, J. MOL. BIOL., (1987), vol. 196, pages 901 - 917 | - KOHLER ET AL., NATURE, (1975), vol. 256, page 495 | - CLACKSON ET AL., NATURE, (1991), vol. 352, pages 624 - 628 | - MARKS ET AL., J. MOL. BIOL., (1991), vol. 222, pages 581 - 597 | - LONBERG, N. ET AL., NATURE, (1994), vol. 368, pages 856 - 859 | - LONBERG, N., Handbook of Experimental Pharmacology, (1994), vol. 113, pages 49 - 101 | - LONBERG, N.; HUSZAR, D., INTERN. REV. IMMUNOL., (1995), vol. 13, pages 65 - 93 | - HARDING, F., LONBERG, N. ANN. N.Y. ACAD. SCI, (1995), vol. 764, pages 536 - 546 | - TAYLOR, L. ET AL., NUCLEIC ACIDS RESEARCH, (1992), vol. 20, pages 6287 - 6295 | - CHEN, J. ET AL., INTERNATIONAL IMMUNOLOGY, (1993), vol. 5, pages 647 - 656 | - TUAILLON ET AL., J. IMMUNOL., (1994), vol. 152, pages 2912 - 2920 | - TAYLOR, L. ET AL., INTERNATIONAL IMMUNOLOGY, (1994), vol. 6, pages 579 - 591 | - FISHWILD, D. ET AL., NATURE BIOTECHNOLOGY, (1996), vol. 14, pages 845 - 851 | - CHEN ET AL., EMBO J., (1993), vol. 12, pages 821 - 830 | - HOOGENBOOM ET AL., J. MOL. BIOL., (1991), vol. 227, page 381 | - VAUGHAN ET AL., NATURE BIOTECH, (1996), vol. 14, page 309 | - HANES; PLUCTHAU, PNAS USA, (1997), vol. 94, pages 4937 - 4942 | - PARMLEY; SMITH, GENE, (1988), vol. 73, pages 305 - 318 | - SCOTT, TIBS, (1992), vol. 17, pages 241 - 245 | - CWIRLA ET AL., PNAS USA, (1990), vol. 87, pages 6378 - 6382 | - RUSSEL ET AL., NUCL. ACIDS RESEARCH, (1993), vol. 21, pages 1081 - 1085 | - HOOGENBOOM ET AL., IMMUNOL. REVIEWS, (1992), vol. 130, pages 43 - 68 | - CHISWELL; MCCAFFERTY, TIBTECH, (1992), vol. 10, pages 80 - 84 | - MERCHANT ET AL., NATURE BIOTECH, (1998), vol. 16, pages 677 - 681 | - AKKERDAAS, VAN REE ET AL., ALLERGY, (1995), vol. 50, no. 3, pages 215 - 220 | - DE GROOT ET AL., J. ALLERGY CLIN. IMMUNOL., (1988), vol. 82, page 778 | - LAEMMLI, NATURE, (1970), vol. 227, no. 5259, pages 680 - 5 |